The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or refractory B-cell Non-Hodgkin Lymphoma. The safety of this treatment will also be studied.
Tumor biopsy positive for CD19 or CD20 at >/= 1% by immunohistochemistry or flow cytometry.
Age 18-80 years.
Karnofsky performance status >/=60%.
Absolute neutrophil count >/=500/mm3 and platelet count >/=50,000/mm3.
Lymphoma in CR with no measurable sites of disease.
Major surgery <4 weeks prior to first dose of study drug.
Any other severe or uncontrolled disease or condition that might increase the risk associated with study participation.
Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
Single group
ONC-PluReceptor NK cells
DrugGiven by injection
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
